Document Detail

Vasodepressor property of the converting enzyme inhibitor captopril (SQ 14 225): the role of factors other than renin-angiotensin blockade in the rat.
MedLine Citation:
PMID:  6986224     Owner:  NLM     Status:  MEDLINE    
1. The peptide converting enzyme inhibitor captopril was given (1.25 mg/kg intravenously) to normal and nephrectomized rats and rats with renovascular and deoxycorticosterone hypertension. 2. Captopril lowered blood pressure to a small extent in normal and nephrectomized rats. Bradykinin infusion in nephrectomized animals, however, potentiated the vasodepressor action of captopril. 3. Captopril produced a major blood pressure fall in the early stages of Goldblatt two-kidney one-clip hypertension: even when hypertension had been present for more than 4 months, a substantial vasodepressor action was seen. Rats with deoxycorticosterone-induced hypertension also showed a significant blood pressure fall. 4. Captopril was given to salt-loaded and salt-depleted rats in which the renin-angiotensin system had been blocked by infusion of the competitive angiotensin II antagonist saralasin. Captopril still lowered blood pressure in the salt-depleted group. 5. Captopril lowers blood pressure in situations where the renin-angiotensin system is not responsible for blood pressure maintenance. Further, the fall in blood pressure produced in Goldblatt two-kidney one-clip hypertension is greater than would be predicted on the basis of renin-angiotensin blockade. It is likely therefore that captopril lowers blood pressure by an action additional to angiotensin blockade. Bradykinin potentiation is one possible mechanism by which this may take place.
E S Marks; R F Bing; H Thurston; J D Swales
Related Documents :
7018794 - Effect of the converting-enzyme inhibitor sq 14 225 (captopril) in early one-kidney, on...
3042354 - Efficacy of urapidil in the management of essential hypertension. a comparison with cap...
6163004 - Evidence for participation of kinins in the antihypertensive effect of converting enzym...
2261144 - New angiotensin converting enzyme inhibitors. their role in the management of hypertens...
15713024 - Inactivation of soybean trypsin inhibitors and lipoxygenase by high-pressure processing.
6110304 - Ataranalgesia - an intravenous anesthetic technique. experience with 978 administrations.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical science (London, England : 1979)     Volume:  58     ISSN:  0143-5221     ISO Abbreviation:  Clin. Sci.     Publication Date:  1980 Jan 
Date Detail:
Created Date:  1980-04-26     Completed Date:  1980-04-26     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  7905731     Medline TA:  Clin Sci (Lond)     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II / pharmacology
Blood Pressure / drug effects*
Bradykinin / pharmacology
Captopril / pharmacology*
Disease Models, Animal
Hypertension / blood,  physiopathology*
Proline / analogs & derivatives*
Renin / blood
Saralasin / pharmacology
Reg. No./Substance:
11128-99-7/Angiotensin II; 147-85-3/Proline; 34273-10-4/Saralasin; 58-82-2/Bradykinin; 62571-86-2/Captopril; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Scan appearances in hydatid cysts of the liver: analysis of 55 cases.
Next Document:  Response of chronic renovascular hypertension to surgical correction or prolonged blockade of the re...